Aegle Therapeutics Corp filed a Form D with the Securities and Exchange Commission on 2026-03-03.
Aegle Therapeutics Corp filed a Form D notice of an exempt securities offering with the SEC on March 3, 2026. The filing reports $456K sold. Its industry group is Biotechnology. It names Shelley Hartman (Executive Officer, Director), David Schimel (Director), Leon Moulder (Director) (SEC Form D, March 3, 2026).
Sell to companies like Aegle Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aegle Therapeutics Corp.
Free to see. No signup.
More on the people and the money behind Aegle Therapeutics Corp, from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in March 2026, largest first.
Get an email when Aegle Therapeutics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aegle Therapeutics Corp raises, hires or launches. No email unless you switch it on.
Watch Aegle Therapeutics Corp →Get the full cited report on Aegle Therapeutics Corp
What the filing shows about Aegle Therapeutics Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aegle Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Aegle Therapeutics Corp →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aegle Therapeutics Corp See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $456K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Shelley Hartman is named as Executive Officer and Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
David Schimel is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
Leon Moulder is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
Scott Braunstein is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
Steve O'Hara is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
Evangelos Badiavas is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
Mikio Tanji is named as Director on the Form D that Aegle Therapeutics Corp filed with the SEC on 3 March 2026, one of 7 people that filing names.
7 people named on the filing — 1 holding an executive role and 6 as directors only.
Named as of the 2026-03-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aegle Therapeutics Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aegle Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aegle Therapeutics Corp covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aegle Therapeutics CorpYou get an alert in MentionFox the next time this company shows up.
If you're behind Aegle Therapeutics Corp: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Aegle Therapeutics Corp. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/aegle-therapeutics-corp-form-d-26000002